China has a serious epidemic of drug-resistant tuberculosis. MDR tuberculosis is linked to inadequate treatment in both the public health system and the hospital system, especially tuberculosis hospitals; however, primary transmission accounts for most cases. (Funded by the Chinese Ministry of Health.).

Gatekeeper-training programs, designed to increase identification and referral of suicidal individuals, are widespread but largely untested. A group-based randomized trial with 32 schools examined impact of QPR (Question, Persuade, Refer) training on a stratified random sample of 249 staff with one-year average follow-up. To test QPR impact, we introduced and contrasted two models of gatekeeper-training effects in a population: Gatekeeper Surveillance and Gatekeeper Communication. Intent-to-treat analyses showed that training increased self-reported knowledge (ES 0.41) and appraisals of efficacy (ES 1.22) and service access (ES 1.07). Training effects varied dramatically. Appraisals increased most for staff with lowest baseline appraisals, and suicide identification behaviors increased most for staff already communicating with students about suicide and distress. Consistent with the Communication model, increased knowledge and appraisals were not sufficient to increase suicide identification behaviors. Also consistent with the Communication model were results from 2,059 8 th and 10 th graders surveyed showing that fewer with prior suicide attempts endorsed talking to adults about distress. Skill training for staff serving as 'naturalgatekeepers' plus interventions that modify students' help-seeking behaviors are recommended to supplement universal gatekeeper training.

IntroductionRheumatoid arthritis (RA) is a T-cell-mediated systemic autoimmune disease, characterized by synovium inflammation and articular destruction. Bone marrow mesenchymal stem cells (MSCs) could be effective in the treatment of several autoimmune diseases. However, there has been thus far no report on umbilical cord (UC)-MSCs in the treatment of RA. Here, potential immunosuppressive effects of human UC-MSCs in RA were evaluated.MethodsThe effects of UC-MSCs on the responses of fibroblast-like synoviocytes (FLSs) and T cells in RA patients were explored. The possible molecular mechanism mediating this immunosuppressive effect of UC-MSCs was explored by addition of inhibitors to indoleamine 2,3-dioxygenase (IDO), Nitric oxide (NO), prostaglandin E2 (PGE2), transforming growth factor β1 (TGF-β1) and interleukin 10 (IL-10). The therapeutic effects of systemic infusion of human UC-MSCs on collagen-induced arthritis (CIA) in a mouse model were explored.ResultsIn vitro, UC-MSCs were capable of inhibiting proliferation of FLSs from RA patients, via IL-10, IDO and TGF-β1. Furthermore, the invasive behavior and IL-6 secretion of FLSs were also significantly suppressed. On the other hand, UC-MSCs induced hyporesponsiveness of T cells mediated by PGE2, TGF-β1 and NO and UC-MSCs could promote the expansion of CD4+ Foxp3+ regulatory T cells from RA patients. More importantly, systemic infusion of human UC-MSCs reduced the severity of CIA in a mouse model. Consistently, there were reduced levels of proinflammatory cytokines and chemokines (TNF-α, IL-6 and monocyte chemoattractant protein-1) and increased levels of the anti-inflammatory/regulatory cytokine (IL-10) in sera of UC-MSCs treated mice. Moreover, such treatment shifted Th1/Th2 type responses and induced Tregs in CIA.ConclusionsIn conclusion, human UC-MSCs suppressed the various inflammatory effects of FLSs and T cells of RA in vitro, and attenuated the development of CIA in vivo, strongly suggesting that UC-MSCs might be a therapeutic strategy in RA. In addition, the immunosuppressive activitiy of UC-MSCs could be prolonged by the participation of Tregs.

Background The purpose of this study was to evaluate the treatment effectiveness of Carriere Distalizer in comparison to Class II intermaxillary elastics and Forsus. Methods Three groups of patients treated with Class II intermaxillary elastics ( n = 18), Carriere Distalizer ( n = 18), and Forsus appliance ( n = 18) were collected from three private orthodontic practices. Inclusion criteria were as follows: (1) 10–14 years old of start age with permanent dentition, (2) no history of previous orthodontic treatment, (3) complete pre- and post-treatment records, (4) dental Class II division 1 (end-to-end or more), (5) no pre-treatment transverse discrepancy, (6) non-extraction treatment plan, and (7) Class I post-treatment occlusal relationship. The data consisted of cephalometric and study model measurements from pre- and post-treatment records and treatment time. Two-tail Student t test was used to analyze the differences in cephalometric changes and dental corrections between Carriere Distalizer group and Class II elastics/Forsus group. Results All three groups of patients showed no differences in the age of treatment initiation, pre-treatment cephalometric measurements and discrepancy index (DI). The time of Class II correction for Carriere Distalizer was significantly shorter than that for Class II elastics; there was no difference in the length of Class II correction between Carriere Distalizer and Forsus groups. The amount of Class II correction (canine/molar relationship) was significantly lower for Carriere Distalizer when compared with Forsus appliance. Carriere Distalizer, similarly to Class II elastics, did not induce any statistically significant correction in skeletal component (ANB and Wits appraisal). Conclusions There is no clinically significant skeletal correction induced by Carriere Distalizer in growing patients. Carriere Distalizer can be applied to treatment of mild to moderate Class II dental malocclusion over 6 months on average, although the total treatment time may be prolonged due to various side effects. Overall, the Carriere Distalizer appears to be no more effective or efficient than alternatives in the treatment of Class II malocclusion.

No abstract